Active, Not Recruiting
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib - CA180-597
Updated: 2 December, 2021 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Participated in and completed a previous dasatinib protocol (including but not limited to CA180056, CA180363 or CA180227) and is deemed by the investigator to be deriving benefit from dasatinib as defined by the previous protocol - Receiving dasatinib at the time of signature of informed consent - Males and Females, ages 18 and older Exclusion Criteria: - All patients previously discontinued from a dasatinib study for any reason - Any serious or uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy - History of allergy to dasatinib
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
